These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 33503926)

  • 1. Cancer Vaccines: Antigen Selection Strategy.
    Zhao Y; Baldin AV; Isayev O; Werner J; Zamyatnin AA; Bazhin AV
    Vaccines (Basel); 2021 Jan; 9(2):. PubMed ID: 33503926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients.
    Gallou C; Rougeot A; Graff-Dubois S; Kosmatopoulos K; Menez-Jamet J
    Oncotarget; 2016 Sep; 7(37):59417-59428. PubMed ID: 27506946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
    Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colorectal cancer vaccines: Tumor-associated antigens
    Wagner S; Mullins CS; Linnebacher M
    World J Gastroenterol; 2018 Dec; 24(48):5418-5432. PubMed ID: 30622371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A minority of T cells recognizing tumor-associated antigens presented in self-HLA can provoke antitumor reactivity.
    Roex MCJ; Hageman L; Veld SAJ; van Egmond E; Hoogstraten C; Stemberger C; Germeroth L; Einsele H; Falkenburg JHF; Jedema I
    Blood; 2020 Jul; 136(4):455-467. PubMed ID: 32483595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines.
    Menez-Jamet J; Gallou C; Rougeot A; Kosmatopoulos K
    Ann Transl Med; 2016 Jul; 4(14):266. PubMed ID: 27563653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
    Pan RY; Chung WH; Chu MT; Chen SJ; Chen HC; Zheng L; Hung SI
    J Immunol Res; 2018; 2018():4325874. PubMed ID: 30662919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
    Cluff CW
    Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Animal models of human-derived cancer vaccines.
    Herlyn D; Somasundaram R; Li W; Jacob L
    Cell Biophys; 1995 Aug; 27(1):15-30. PubMed ID: 7493396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA vaccine for cancer immunotherapy.
    Yang B; Jeang J; Yang A; Wu TC; Hung CF
    Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer vaccines: harnessing the potential of anti-tumor immunity.
    Suckow MA
    Vet J; 2013 Oct; 198(1):28-33. PubMed ID: 23850019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen-specific vaccines for cancer treatment.
    Tagliamonte M; Petrizzo A; Tornesello ML; Buonaguro FM; Buonaguro L
    Hum Vaccin Immunother; 2014; 10(11):3332-46. PubMed ID: 25483639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in Vaccine Therapies for Breast Cancer.
    Li X; Bu X
    Adv Exp Med Biol; 2017; 1026():315-330. PubMed ID: 29282691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer therapy and vaccination.
    Aly HA
    J Immunol Methods; 2012 Aug; 382(1-2):1-23. PubMed ID: 22658969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide vaccines in breast cancer: The immunological basis for clinical response.
    Peres Lde P; da Luz FA; Pultz Bdos A; Brígido PC; de Araújo RA; Goulart LR; Silva MJ
    Biotechnol Adv; 2015 Dec; 33(8):1868-77. PubMed ID: 26523780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?
    Strioga MM; Darinskas A; Pasukoniene V; Mlynska A; Ostapenko V; Schijns V
    Vaccine; 2014 Jul; 32(32):4015-24. PubMed ID: 24837511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo.
    Okada H; Attanucci J; Giezeman-Smits KM; Brissette-Storkus C; Fellows WK; Gambotto A; Pollack LF; Pogue-Geile K; Lotze MT; Bozik ME; Chambers WH
    Cancer Res; 2001 Mar; 61(6):2625-31. PubMed ID: 11289140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.